Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib
Caroline Bailleux1,*, Guillaume Robert2,3,*, Clémence Ginet2,3, Daniel Re1, Antoine Thyss1, Isabelle Sudaka4, Isabelle Peyrottes5, Paul Hofman6, Patrick Auberger2,3,**and Frederic Peyrade1,**
1 Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
2 INSERM, U1065, TEAM 2, Nice, France
3 University of Nice, Nice, France
4 Laboratory of Hematology, CHU Nice, Nice, France
5 Department of Pathology, Centre Antoine Lacassagne, Nice, France
6 Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, CHU Nice
* Co-first authors
** Co-last authors
Correspondence:
Guillaume Robert, email:
Keywords: hairy-cell leukemia, V600E mutation, relapse, vemurafenib, re-treatment
Received: October 10, 2014 Accepted: December 22, 2014 Published: December 26, 2014
Abstract
Hairy cell leukemia (HCL) is chronic B-cell lymphoproliferative disorder that accounts for 2% of all leukemia. Recent identification of the recurrent V600E BRAF mutation in a majority of HCL patients has led some teams to evaluate the clinical potential of vemurafenib, a BRAF V600 specific inhibitor in a limited number of refractory HCL patients. Recently, we published the case of an HCL patient successfully treated with a low dose of vemurafenib. Eight months after the ending of treatment this patient relapsed. We present here the successful retreatment of this patient with a second line of vemurafenib. Our data suggest for the first time that vemurafenib at the dose of 240 mg once a day could be sufficient to maintain a complete hematological remission after an initial induction treatment with low-dose vemurafenib (2 x 240 mg) daily without inducing major toxicity.
